|

CCCG-ALCL-2020 for Chinese Children and Adolescents with Newly Diagnosed High-risk ALCL

RECRUITINGPhase 3Sponsored by Children's Cancer Group, China
Actively Recruiting
PhasePhase 3
SponsorChildren's Cancer Group, China
Started2021-03-01
Est. completion2026-03-01
Eligibility
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT04881838

Summary

A prospective study on the efficacy of modified ALCL99 regimens in the treatment of the current Chinese pediatric and adolescent high-risk ALCL and compared with our historical data.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

* Patient must be ≤ 18 years at the time of diagnosis
* Newly diagnosed patients with histologically confirmed high-risk anaplastic large cell lymphoma
* No congenital immunodeficiency, HIV infection, or prior organ transplant

Exclusion Criteria:

* Patients have received prior cytotoxic chemotherapy/target therapy/radiation, if any steroid applied, total prior steroids dosage \> Dexamethasone 40 mg/m2 for the current diagnosis or any cancer
* Patients have overwhelming infection, and a life expectancy of \< 2 weeks

Conditions2

CancerPediatric Anaplastic Large Cell Lymphoma

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.